Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03785249 · ClinicalTrials.gov registry record · Phase 1

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

A Phase 1 study of Advanced Cancer and Metastatic Cancer, sponsored by Mirati Therapeutics.

Active
Registry status
Phase 1
Development phase
731
Enrollment target
20
Study locations

NCT03785249 is a Phase 1 study of Advanced Cancer and Metastatic Cancer that is active but no longer recruiting, run by Mirati Therapeutics. The registered enrollment target is 731 participants, above the 240-participant average among 122 other Advanced Cancer trials with a reported enrollment target (205% higher). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03785249, a Phase 1 study of Advanced Cancer and Metastatic Cancer, is active but no longer recruiting, sponsored by Mirati Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
731 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

Conditions Studied

Advanced Cancer Metastatic Cancer Malignant Neoplastic Disease

Interventions

  • DRUG Pembrolizumab
  • DRUG Cetuximab
  • DRUG Afatinib
  • DRUG MRTX849

Study Locations (20)

California

  • Local Institution - 001-840-B - Bellflower
  • Local Institution - 001-834 - Beverly Hills
  • Local Institution - 001-843 - Duarte
  • Local Institution - 001-850-K - Dublin
  • Local Institution - 001-851 - Fullerton
  • Local Institution - 001-840-C - Harbor City
  • Local Institution - 001-805 - La Jolla
  • Local Institution - 001-779 - Los Alamitos
  • Local Institution - 001-840 - Los Angeles
  • Local Institution - 001-578 - Los Angeles
  • Local Institution - 001-847 - Newport Beach
  • Local Institution - 001-850-B - Oakland
  • Local Institution - 001-803 - Orange
  • Local Institution - 001-850-C - Roseville
  • Local Institution - 001-850-J - Sacramento

Arizona

  • Local Institution - 001-821 - Phoenix
  • Local Institution - 001-873-A - Tucson
  • Local Institution - 001-873 - Tucson

Alabama

  • Local Institution - 001-826 - Birmingham

Alaska

  • Local Institution - 001-965 - Anchorage

Trial Details

FieldValue
Enrollment Target 731 participants
Start Date 2019-01-15
Est. Completion 2026-12-31
Phase Phase 1

Sponsor

Mirati Therapeutics

49 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03785249

The ClinicalTrials.gov registry entry for NCT03785249 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 731 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 240-participant average among 122 other Advanced Cancer trials with a reported enrollment target (205% higher). The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT03785249 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.

Frequently Asked Questions

What is clinical trial NCT03785249 about?

NCT03785249 is a clinical study titled "Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1". This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

What is the current status of trial NCT03785249?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 731 participants. The study started on 2019-01-15. Estimated completion is 2026-12-31.

What conditions does trial NCT03785249 study?

This clinical trial studies the following conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease.

What interventions are being tested in trial NCT03785249?

The interventions under investigation include: Pembrolizumab (DRUG), Cetuximab (DRUG), Afatinib (DRUG), MRTX849 (DRUG).

Who is sponsoring clinical trial NCT03785249?

This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03785249 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Cancer

All registered trials for this condition

Metastatic Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.